These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 20402710)

  • 1. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
    Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
    Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.
    Fraguas D; Merchán-Naranjo J; Laita P; Parellada M; Moreno D; Ruiz-Sancho A; Cifuentes A; Giráldez M; Arango C
    J Clin Psychiatry; 2008 Jul; 69(7):1166-75. PubMed ID: 18588363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
    Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).
    Bond DJ; Kauer-Sant'Anna M; Lam RW; Yatham LN
    J Affect Disord; 2010 Jul; 124(1-2):108-17. PubMed ID: 19914720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients.
    Arango C; Giráldez M; Merchán-Naranjo J; Baeza I; Castro-Fornieles J; Alda JA; Martínez-Cantarero C; Moreno C; de Andrés P; Cuerda C; de la Serna E; Correll CU; Fraguas D; Parellada M
    J Am Acad Child Adolesc Psychiatry; 2014 Nov; 53(11):1179-90,1190.e1-4. PubMed ID: 25440308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
    Lee SY; Park MH; Patkar AA; Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics.
    Cuerda C; Merchan-Naranjo J; Velasco C; Gutierrez A; Leiva M; de Castro MJ; Parellada M; Giráldez M; Bretón I; Camblor M; García-Peris P; Dulín E; Sanz I; Desco M; Arango C
    Clin Nutr; 2011 Oct; 30(5):616-23. PubMed ID: 21492975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders.
    Prabhakar M; Haynes WG; Coryell WH; Chrischilles EA; Miller del D; Arndt S; Ellingrod VL; Warren L; Fiedorowicz JG
    Pharmacotherapy; 2011 Aug; 31(8):806-12. PubMed ID: 21923607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
    Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in body mass index z-scores and weight status in a Dutch pediatric psychiatric population with and without use of second-generation antipsychotics.
    de Hoogd S; Overbeek WA; Heerdink ER; Correll CU; de Graeff ER; Staal WG
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):166-73. PubMed ID: 22506734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
    Ronsley R; Nguyen D; Davidson J; Panagiotopoulos C
    Can J Psychiatry; 2015 Oct; 60(10):441-50. PubMed ID: 26720191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deterioration of metabolic parameters during short-term psychiatric inpatient treatment: a prospective naturalistic study.
    Rittmannsberger H; Fellinger J; Foff C; Walli G; Zaunmüller T
    Int J Psychiatry Clin Pract; 2012 Mar; 16(1):8-17. PubMed ID: 22122649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
    Maayan L; Correll CU
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between second-generation antipsychotics and changes in body mass index in adolescents.
    Ghate SR; Porucznik CA; Said Q; Hashibe M; Joy E; Brixner DI
    J Adolesc Health; 2013 Mar; 52(3):336-43. PubMed ID: 23427784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics.
    O'Donoghue B; Schäfer MR; Becker J; Papageorgiou K; Amminger GP
    Early Interv Psychiatry; 2014 Aug; 8(3):276-80. PubMed ID: 23968390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study.
    Baeza I; Vigo L; de la Serna E; Calvo-Escalona R; Merchán-Naranjo J; Rodríguez-Latorre P; Arango C; Castro-Fornieles J
    Eur Child Adolesc Psychiatry; 2017 Jan; 26(1):35-46. PubMed ID: 27209421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Eating disorders in psychiatric patients during treatment with second generation antipsychotics].
    Vasilenko LM; Gorobets LN; Bulanov VS; Litvinov AV; Ivanova GP; Tsarenko MA; Polyakovskaya TP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(7):60-67. PubMed ID: 26356516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
    Byerly MJ; Nakonezny PA; Bettcher BM; Carmody T; Fisher R; Rush AJ
    Schizophr Res; 2006 Sep; 86(1-3):244-50. PubMed ID: 16730951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.
    Karagianis J; Williams R; Davis L; Procyshyn R; Monga N; Hanley J; Chandrasena R; Thakur A; Dickson R
    Curr Med Res Opin; 2009 Sep; 25(9):2121-32. PubMed ID: 19601707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.